In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
|Articles|May 31, 2023
What Affects Neutralizing Antibody Durability? A Comparative Study of COVID-19 Vaccines
Author(s)Nina Cosdon
Neutralizing antibodies were initially lowest among Janssen vaccine recipients, but this all changed 6 months after vaccination.
Advertisement
The
A head-to-head
This study investigated the durability of neutralizing antibodies (nABs) in healthy community volunteers who received three different COVID-19 vaccines:
One month after vaccination, Pfizer-BioNTech recipients had an antibody response 21 times higher than those who received Janssen, while Moderna recipients boasted a vaccine response 51 times higher than the Janssen cohort.
However, the results showed that nABs declined over the 6 months of follow-up for recipients of Pfizer-BioNTech and Moderna, while the nABs in Janssen recipients increased significantly. At the 6-month time point, nABs to Janssen were significantly higher than nABs to Pfizer-BioNTech and equivalent to Moderna. Older age was associated with lower nABs for participants who received Pfizer-BioNTech and Janssen, but not for those who received Moderna.
A higher baseline body mass index (BMI) was associated with lower nABs for Janssen recipients, but this trend did not apply to patients who received other vaccines. Women and non-smokers showed higher nABs compared to men and current smokers, respectively.
The study’s findings suggest that the durability of nAB responses differs by vaccine type and several sociodemographic factors. However, the study’s limitations should be noted, including a relatively small sample size for some vaccine types, the absence of data on T-cell immunity, and the use of a pseudovirus assay to measure nAB titers.
Overall, this study contributes to the understanding the neutralizing antibody response durability of and the impact of vaccine type and individual factors on vaccine efficacy. These findings can inform public health decisions around booster recommendations and vaccine deployment strategies.
Advertisement
Related to this article
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.
Projected disease burden from declining childhood vaccine coverage shows increases in vaccine-preventable diseases. Benjamin Lopman, PhD, provides insights on how VaxImpactMap works and the potential long-term disease consequences of decreased immunization rates.
A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Advertisement
Advertisement